3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
4
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Gastric Cancer
1
Interventions
pembrolizumab
23
Gemcitabine
9
Nivolumab
7
Carboplatin
7
Trastuzumab
6
Early Intervention, Educational
6
avelumab
5
atezolizumab
5
Docetaxel
5
Cisplatin
5
cemiplimab
4
Standard of Care
4
Psychiatric Rehabilitation
4
Paclitaxel
4
Methods
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Fluorouracil
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
pertuzumab
3
fludarabine
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
rucaparib
×
Gastrointestinal
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts